GEAP202014783A - A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic - Google Patents

A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Info

Publication number
GEAP202014783A
GEAP202014783A GEAP202014783A GEAP2020014783A GEAP202014783A GE AP202014783 A GEAP202014783 A GE AP202014783A GE AP202014783 A GEAP202014783 A GE AP202014783A GE AP2020014783 A GEAP2020014783 A GE AP2020014783A GE AP202014783 A GEAP202014783 A GE AP202014783A
Authority
GE
Georgia
Prior art keywords
excipient
anticholinergic
corticosteroid
adrenergic
beta
Prior art date
Application number
GEAP202014783A
Other languages
English (en)
Georgian (ka)
Inventor
Francesca Schiaretti
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP202014783(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of GEAP202014783A publication Critical patent/GEAP202014783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
GEAP202014783A 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic GEAP202014783A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16

Publications (1)

Publication Number Publication Date
GEAP202014783A true GEAP202014783A (en) 2020-04-27

Family

ID=54548062

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202014783A GEAP202014783A (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
GEAP201614783A GEP20207157B (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201614783A GEP20207157B (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Country Status (35)

Country Link
US (4) US10086004B2 (enExample)
EP (3) EP3620176B1 (enExample)
JP (1) JP6963548B2 (enExample)
KR (1) KR20180082443A (enExample)
CN (1) CN108289962B (enExample)
AR (1) AR106688A1 (enExample)
AU (1) AU2016356858B2 (enExample)
CL (1) CL2018001298A1 (enExample)
CO (1) CO2018005141A2 (enExample)
CY (3) CY1123042T1 (enExample)
DK (3) DK3377108T3 (enExample)
EA (1) EA037716B1 (enExample)
ES (3) ES2895687T3 (enExample)
GE (2) GEAP202014783A (enExample)
HR (3) HRP20211600T1 (enExample)
HU (3) HUE056260T2 (enExample)
IL (1) IL259329B (enExample)
LT (3) LT3620176T (enExample)
MA (3) MA43256B1 (enExample)
MD (3) MD3620176T2 (enExample)
ME (1) ME03778B (enExample)
MX (1) MX379853B (enExample)
MY (1) MY186229A (enExample)
PE (1) PE20181488A1 (enExample)
PH (1) PH12018501022A1 (enExample)
PL (3) PL3628331T3 (enExample)
PT (3) PT3377108T (enExample)
RS (3) RS62404B1 (enExample)
SA (1) SA518391570B1 (enExample)
SG (2) SG11201804050QA (enExample)
SI (3) SI3620176T1 (enExample)
TW (1) TWI731891B (enExample)
UA (1) UA125019C2 (enExample)
WO (1) WO2017085004A1 (enExample)
ZA (1) ZA201803168B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206619A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
US11566036B2 (en) * 2019-03-27 2023-01-31 Kemin Industries, Inc. Methods for preparing metal carboxylates in one-pot reaction
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
SI1658872T2 (sl) 2002-07-31 2019-12-31 Chiesi Farmacetuici S.P.A. Inhalator prahu
HRP20140582T4 (hr) * 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
SG186427A1 (en) * 2010-06-22 2013-01-30 Chiesi Farma Spa Dry powder formulation comprising an antimuscarinic drug
SI3345904T1 (sl) * 2012-12-06 2020-09-30 Chiesi Farmaceutici S.P.A. Spojine z aktivnostjo antagonista muskarinskih receptorjev in agonista beta2 adrenergičnih receptorjev
RU2661877C2 (ru) * 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
NZ715797A (en) * 2013-07-11 2020-06-26 Chiesi Farm Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Also Published As

Publication number Publication date
DK3620176T3 (da) 2021-09-20
EA037716B1 (ru) 2021-05-13
GEP20207157B (en) 2020-10-12
SG10201912093YA (en) 2020-02-27
AR106688A1 (es) 2018-02-07
EP3377108A1 (en) 2018-09-26
CY1123042T1 (el) 2021-10-29
ES2783855T3 (es) 2020-09-18
CY1124475T1 (el) 2022-07-22
DK3628331T3 (da) 2021-09-27
MX2018005977A (es) 2018-08-29
IL259329B (en) 2020-10-29
AU2016356858B2 (en) 2021-06-24
HUE049751T2 (hu) 2020-10-28
SI3377108T1 (sl) 2020-05-29
PE20181488A1 (es) 2018-09-18
PH12018501022B1 (en) 2018-12-17
BR112018009807A8 (pt) 2019-02-26
CY1124490T1 (el) 2022-07-22
US10086004B2 (en) 2018-10-02
CN108289962B (zh) 2021-09-14
EP3620176B1 (en) 2021-08-11
PT3628331T (pt) 2021-10-20
JP2019501876A (ja) 2019-01-24
EP3620176A1 (en) 2020-03-11
JP6963548B2 (ja) 2021-11-10
HUE056260T2 (hu) 2022-02-28
RS62404B1 (sr) 2021-10-29
ES2895687T3 (es) 2022-02-22
MD3628331T2 (ro) 2021-12-31
NZ742474A (en) 2024-11-29
ES2891073T3 (es) 2022-01-26
HRP20200537T1 (hr) 2020-06-26
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
PT3377108T (pt) 2020-04-08
MA50488B1 (fr) 2021-09-30
ZA201803168B (en) 2019-07-31
MA50487A (fr) 2021-04-28
MA50487B1 (fr) 2021-09-30
BR112018009807A2 (pt) 2018-11-06
US20210177866A1 (en) 2021-06-17
MA43256B1 (fr) 2020-05-29
LT3377108T (lt) 2020-07-10
US11628175B2 (en) 2023-04-18
EA201890966A1 (ru) 2018-11-30
IL259329A (en) 2018-07-31
EP3628331B1 (en) 2021-08-11
TW201722404A (zh) 2017-07-01
MD3377108T2 (ro) 2020-07-31
MY186229A (en) 2021-06-30
CA3005290A1 (en) 2017-05-26
PL3628331T3 (pl) 2021-11-08
MX379853B (es) 2025-03-11
HRP20211598T1 (hr) 2022-01-07
AU2016356858A1 (en) 2018-05-31
HRP20211600T1 (hr) 2022-01-21
SA518391570B1 (ar) 2022-03-27
PT3620176T (pt) 2021-09-28
SG11201804050QA (en) 2018-06-28
LT3628331T (lt) 2021-11-10
WO2017085004A1 (en) 2017-05-26
ME03778B (me) 2021-04-20
RS60171B1 (sr) 2020-05-29
PL3620176T3 (pl) 2021-11-22
MA43256A (fr) 2018-09-26
EP3377108B1 (en) 2020-02-19
SI3628331T1 (sl) 2021-11-30
PL3377108T3 (pl) 2020-09-07
CL2018001298A1 (es) 2018-09-14
PH12018501022A1 (en) 2018-12-17
TWI731891B (zh) 2021-07-01
MA50488A (fr) 2021-05-19
CN108289962A (zh) 2018-07-17
KR20180082443A (ko) 2018-07-18
RS62506B1 (sr) 2021-11-30
US20170136035A1 (en) 2017-05-18
US10772896B2 (en) 2020-09-15
EP3628331A1 (en) 2020-04-01
UA125019C2 (uk) 2021-12-29
SI3620176T1 (sl) 2021-11-30
US20200368252A1 (en) 2020-11-26
US10966991B2 (en) 2021-04-06
DK3377108T3 (da) 2020-04-20
US20180360849A1 (en) 2018-12-20
CO2018005141A2 (es) 2018-09-28
HUE056441T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
GEAP202014783A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
GEAP202014782A (en) Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic
AR129501A2 (es) FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
PE20140101A1 (es) Formulacion para inhalacion que comprende aclidinio
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
WO2015033302A3 (en) Fulvestrant compositions
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2015012529A (es) Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
MX394644B (es) Excipiente a base de proteínas para ingredientes farmacéuticos activos.
MY170427A (en) Novel pharmaceutical composition
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
MX2016008527A (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
EA033247B1 (ru) Способ получения сухих порошковых композиций для ингаляций
MX374484B (es) Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico.
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
CO2017011220A2 (es) Proceso para la fabricación de mezclas de polvo seco
MX2020010928A (es) Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
EA201692456A1 (ru) Способ получения составов для ингаляции